Business Description
Cumberland Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2307701092
Description
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.99 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.62 | |||||
| Debt-to-EBITDA | 7.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.35 | |||||
| Beneish M-Score | -3.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.9 | |||||
| 3-Year EPS without NRI Growth Rate | -4.1 | |||||
| 3-Year FCF Growth Rate | 21.9 | |||||
| 3-Year Book Growth Rate | -12.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.96 | |||||
| 9-Day RSI | 62 | |||||
| 14-Day RSI | 54.17 | |||||
| 6-1 Month Momentum % | -16.18 | |||||
| 12-1 Month Momentum % | -9.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.11 | |||||
| Cash Ratio | 0.65 | |||||
| Days Inventory | 532.37 | |||||
| Days Sales Outstanding | 114.96 | |||||
| Days Payable | 695.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2 | |||||
| Shareholder Yield % | 5.55 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.66 | |||||
| Operating Margin % | -24.16 | |||||
| Net Margin % | -15.88 | |||||
| FCF Margin % | 14.26 | |||||
| ROE % | -17.9 | |||||
| ROA % | -7.11 | |||||
| ROIC % | -15.83 | |||||
| ROC (Joel Greenblatt) % | -82.59 | |||||
| ROCE % | -9.21 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 8.15 | |||||
| PS Ratio | 0.64 | |||||
| PB Ratio | 0.84 | |||||
| Price-to-Tangible-Book | 4.09 | |||||
| Price-to-Free-Cash-Flow | 4.5 | |||||
| Price-to-Operating-Cash-Flow | 4.16 | |||||
| EV-to-EBIT | -4.31 | |||||
| EV-to-EBITDA | 9.22 | |||||
| EV-to-Revenue | 0.61 | |||||
| EV-to-FCF | 4.29 | |||||
| Price-to-Projected-FCF | 0.43 | |||||
| Price-to-Median-PS-Value | 0.27 | |||||
| Earnings Yield (Greenblatt) % | -23.2 | |||||
| FCF Yield % | 22.61 | |||||
| Forward Rate of Return (Yacktman) % | 5.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cumberland Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 39.553 | ||
| EPS (TTM) ($) | -0.441 | ||
| Beta | 0 | ||
| Volatility % | 42.66 | ||
| 14-Day RSI | 54.17 | ||
| 14-Day ATR ($) | 0.102672 | ||
| 20-Day SMA ($) | 1.66878 | ||
| 12-1 Month Momentum % | -9.52 | ||
| 52-Week Range ($) | 1.43 - 2.3587 | ||
| Shares Outstanding (Mil) | 14.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cumberland Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cumberland Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cumberland Pharmaceuticals Inc Frequently Asked Questions
What is Cumberland Pharmaceuticals Inc(CPIX)'s stock price today?
The current price of CPIX is $1.76. The 52 week high of CPIX is $2.36 and 52 week low is $1.43.
When is next earnings date of Cumberland Pharmaceuticals Inc(CPIX)?
The next earnings date of Cumberland Pharmaceuticals Inc(CPIX) is 2024-05-15 Est..
Does Cumberland Pharmaceuticals Inc(CPIX) pay dividends? If so, how much?
Cumberland Pharmaceuticals Inc(CPIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers